Prospective Stage-Stratified Histopathologic Study and Proposed Disease-Evolution Model of Gluteal Permanent Synthetic Filler Complications
September 7, 2026 updated by: Research Inc
This prospective biospecimen cohort will collect and analyze tissue from adults undergoing clinically indicated surgery for gluteal permanent synthetic filler disease.
Two blinded pathologists will score foreign material burden, inflammation, fibrosis, necrosis, vascular and lymphatic injury, and deep-tissue involvement.
Histopathologic severity will be compared across clinical-radiologic stages and time since injection.
The study will propose a cross-sectional disease-evolution framework and assess the reproducibility of the scoring system.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
Participants will be enrolled before clinically indicated biopsy or filler-removal surgery.
Exposure history, symptoms, physical findings, and MRI stage will be recorded using standardized forms.
During surgery, samples from mapped tissue planes will be collected without extending the planned excision.
Two pathologists blinded to clinical stage will independently grade eight tissue-injury domains and generate a composite severity score.
Disagreements will undergo adjudication.
The study will evaluate associations between tissue findings, time since injection, and clinical-radiologic stage and will use exploratory clustering to identify histopathologic phenotypes.
Because participants are sampled at one operation, the resulting model will be described as a proposed cross-sectional natural-history framework.
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Edison Osorio, MD, Plastic surgeon
- Phone Number: +573226140611
- Email: info@edisonosorio.com
Study Locations
-
-
Antioquia
-
Medellín, Antioquia, Colombia
- Clinica Bioforma
-
Contact:
- Edison Osorio, MD, Plastic surgeon
- Phone Number: +573226140611
- Email: info@edisonosorio.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults undergoing biopsy or surgical removal of gluteal tissue affected by permanent synthetic filler, spanning early exposure through advanced disease with ulceration or necrosis.
Description
Inclusion Criteria:
Age 18 years or older.
- Prior gluteal injection of a permanent or unknown nonresorbable filler.
- Clinically indicated biopsy or surgical excision yielding tissue suitable for histopathologic evaluation.
- Available history of approximate injection date and standardized preoperative clinical staging.
- Written consent for tissue analysis and optional future use of deidentified specimens.
Exclusion Criteria:
- Specimen composed only of scar or skin without tissue from the filler-affected region.
- Insufficient tissue quality for routine histology.
- Acute bacterial infection that precludes distinction of the underlying chronic tissue response unless infection is itself a prespecified advanced-stage feature.
- Prior oncologic radiation to the sampled gluteal region.
- Declined consent for research use of surgical tissue.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Prospective Histopathology Cohort
Samples will be obtained from predefined superficial, interface, deep, and visibly abnormal regions without extending the clinically indicated excision.
Each sample will be oriented and linked to an MRI/operative map.
|
Samples will be obtained from predefined superficial, interface, deep, and visibly abnormal regions without extending the clinically indicated excision.
Each sample will be oriented and linked to an MRI/operative map.
Linked arm/group(s): Prospective Histopathology Cohort.
Two pathologists will independently grade foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis on 0-to-3 ordinal scales.
The proposed composite ranges from 0 to 24; the manual will be locked before the first analytic read.
Linked arm/group(s): Prospective Histopathology Cohort.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite Histopathologic Severity Score by Clinical-Radiologic Stage
Time Frame: At the index operation and final blinded histopathology assessment of the surgical specimen. 3 months
|
Sum of eight prespecified 0-to-3 domain scores: foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis.
Total score ranges from 0 to 24; higher scores indicate more severe tissue injury.
|
At the index operation and final blinded histopathology assessment of the surgical specimen. 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of Individual Histopathologic Features
Time Frame: At final histopathology assessment of the index surgical specimen. 3 months
|
Proportion of participants with each prespecified feature and distribution of each 0-to-3 domain grade.
|
At final histopathology assessment of the index surgical specimen. 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Histopathologic Phenotype Classification
Time Frame: After completion of tissue collection and database lock, using data from the index specimen. 1 year
|
Data-driven clusters or latent classes based on the eight domains, integrated with clinical and MRI stage to generate a proposed disease-evolution framework.
|
After completion of tissue collection and database lock, using data from the index specimen. 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Edison Osorio, MD, plastic surgery
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Osorio E, Ramirez B, Herrera O, Suarez C, Ciro C, Varela A. Three-flap Technique: Comprehensive Approach for Biopolymer Removal in the Gluteal and Lumbar Regions. Plast Reconstr Surg Glob Open. 2026 Jul 23;14(7):e7870. doi: 10.1097/GOX.0000000000007870. eCollection 2026 Jul.
- Pachon Suarez JE, Tello VZR, Cifuentes RCR, Cuadros AMP, Salazar MC. Biopolymers: Histopathologic Case Series of Patients with Permanent Synthetic Fillers Presenting Chronic Granulomatous Reaction and Hypercalcemia. Plast Reconstr Surg Glob Open. 2024 Oct 15;12(10):e6159. doi: 10.1097/GOX.0000000000006159. eCollection 2024 Oct.
- Pachon Suarez JE, Salazar MC, Rizo VZ. Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease. Plast Reconstr Surg Glob Open. 2022 Feb 24;10(2):e4137. doi: 10.1097/GOX.0000000000004137. eCollection 2022 Feb.
- Xu T, Zhang J, Zhu Y, Zhao W, Pan C, Ma H, Zhang L. A poly(hydroxyethyl methacrylate)-Ag nanoparticle porous hydrogel for simultaneous in vivo prevention of the foreign-body reaction and bacterial infection. Nanotechnology. 2018 Sep 28;29(39):395101. doi: 10.1088/1361-6528/aad257. Epub 2018 Jul 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
September 1, 2026
First Submitted That Met QC Criteria
September 7, 2026
First Posted (Actual)
September 9, 2026
Study Record Updates
Last Update Posted (Actual)
September 9, 2026
Last Update Submitted That Met QC Criteria
September 7, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 009 (Nahrain Medical Research Collective (NMRC))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
not considered in the informed consent of the patients
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.